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The M1 alanyl aminopeptidase and M17 leucyl aminopeptidase are critical to the growth and 
development of malaria parasites inside host erythrocytes. Potent aminopeptidase inhibitors kill 
malaria parasites in culture and are also active in vivo against murine malaria. Functional 
recombinant enzyme studies have been used to decipher the three-dimensional structures of both 
enzymes that together with new and specific inhibitors are facilitating structure-activity-
relationship (SAR) and functional studies. Here we review the progress made in our knowledge 
of these two enzymes which is bringing them closer to being validated anti-malarial drug targets. 
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Malaria is endemic in about 106 countries and threatens half of the world’s population.
1-3
 There 
are over 300 million cases per year and although current concerted interventions have proved 
successful in reducing annual deaths these still range between 850,000 and 1 million each year.
3-5
 
Malaria is caused by protozoan parasites of the genus Plasmodium. While five species of 
Plasmodium infect humans, P. falciparum is responsible for most deaths, particularly in children 
and pregnant women in the African continent.
3-5
 P. falciparum malaria is transmitted by infected 
female Anopheline mosquitoes that inject infective sporozoites into the human bloodstream 
when they bite. These sporozoites migrate to the liver where they invade hepatocytes and form 
exoerythrocytic schizonts, each containing approximately 30,000 merozoites. After a period of 
between 8 and 11 days, the schizont-infected hepatocytes rupture releasing mature merozoites 
into the bloodstream where they infect host erythrocytes. Within the erythrocytes the parasites 
progress through strictly regulated phases of asexual development known as rings (22-24 hours), 
trophozoites (10-12 hours) and schizonts (6-10 hours). Mature schizonts develop into as many as 
32 merozoites that, following rupture of the erythrocyte, are released and quickly invade other 
erythrocytes to begin the next cycle. This repeated cycle leads to a rapidly increasing number of 
infected cells (parasitaemia) which, if uncontrolled, can lead to death.
3
  
The clinical manifestations of malaria occur when parasites rupture from the erythrocytes. It 
is not surprising, therefore, that many new anti-malarial drug development strategies focus on 
targeting the asexual intra-erythrocytic stages of Plasmodium development.
2,3
 Intraerythrocytic 
parasites are metabolically active and breakdown 65-75% of host cell haemoglobin in a 
hydrolytic process that ultimately releases free aminoacids that are used by the parasite in protein 
synthesis.
6,7
 Haemoglobin digestion is also considered essential for the maintenance of osmotic 
pressure within the infected erythrocyte, a process that is believed to prevent premature 
erythrocyte lysis (colloid osmotic hypothesis).
7
 However, as the inhibition of haemoglobin 
digestion with peptidase inhibitors does not cause premature osmotic lysis of infected cells, 
Naughton et al.
8
 suggested that its primary function is nutritional. Interestingly, Krugliak et al.
9
 
found that only 16% of degraded haemoglobin is used by parasites for protein synthesis, the rest 
being converted into haemozoin or disposed of by alternative mechanisms. Malaria parasites also 
have the ability to synthesize several aminoacids de novo (including asparagine, glutamine, 
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glycine, proline, aspartate and glutamate) and can acquire additional aminoacids from exogenous 
sources such as host plasma.
10,11
 Isoleucine, which is the only aminoacid absent from human 
haemoglobin, is obtained from outside of the red blood cell by exchanging it with leucine, an 
abundant aminoacid in haemoglobin
12
. Malaria parasites have been shown to grow in culture 
medium lacking all aminoacids except isoleucine.
11,13
 
Inside the erythrocyte the parasite resides within its own membrane-protected space, known 
as the parasitophorus vacuole (PV), and is therefore not in direct contact with the red cell 
milieu.
6,7,13,14
 The contents of the host erythrocyte cytoplasm are actively taken into the parasite 
via cytostomes and then transported in vesicles to a specialized organelle known as the food or 
digestive vacuole (DV) for breakdown.
6,13,14
 The DV is maintained at a low pH, estimated at 5.2, 
at which most of the DV proteases function best, although a low pH is also likely to induce 
structural relaxation or denaturation of haemoglobin protein making it more susceptible to 
proteolytic hydrolysis.
6,13,14
 By contrast, the pH of the malaria cell cytoplasm is 7.2.
14-16
  
Catabolism of host haemoglobin in the DV involves a number of endopeptidases of various 
mechanistic classes; these include several aspartic proteases termed plasmepsins (plasmepsins I, 
II, IV and histo-aspartic protease), three cysteine proteases termed falcipains (falcipains 2, 2′ and 
3) and a single metallo-protease termed falcilysin. The combined and simultaneous action of 
these proteases degrades haemoglobin into small peptides of about 8-10 aminoacids long.
17-20
 As 
the DV falcipains and plasmepsins have historically been a focus of anti-malaria drug discovery 
efforts much is known about their biochemistry, structure and function.
13,18,19
 However, knock-
out experiments have shown that the DV plasmepsins and falcipains 2 and 2′ are individually not 
essential to parasite survival, and because of this redundancy between the function of these 
enzyme classes it has proved difficult to develop drugs that effectively block the digestive 
process within the DV.
21-24
 
Peptides produced in the DV may be further processed to dipeptides by a dipeptidyl amino-
peptidase I, an orthologue of mammalian cathepsin C.
25,26
 Small peptides and dipeptides may 




Aminopeptidases are essential in releasing aminoacids from haemoglobin-derived peptides 
and are thus central to the growth and development of malaria parasites in the erythrocyte.
31,34
 
The P. falciparum genome encodes five aminopeptidases that are potential candidate enzymes 
for releasing free aminoacids from haemoglobin-derived peptides;
34
 these include three highly 
specific enzymes, a post-prolyl aminopeptidase (PfAPP) that is located in the DV and an aspartic 
aminopeptidase (M18AAP) and a prolyl aminopeptidase (S33PAP) located in the cytoplasm. 
These three enzymes may function in concert with the M1 alanyl aminopeptidase (M1AAP) and 
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2. M1 Alanyl Aminopeptidase (PfM1AAP) and M17 Leucine Aminopeptidase 
(PfM17LAP) 
 
The presence of aminopeptidase activity in malaria cell extracts with a pH optimum in the 
neutral range was first described over thirty years ago,
35-39
 and was postulated to be involved in 
the release of free aminoacids from host hemoglobin by Slomianny et al.
37
 The proteins 
responsible for the neutral aminopeptidase activity in extracts obtained from various malaria 
species have been characterized as ranging from 63 to 180 kDa.
27,29,35-39
 Biochemical analysis of 
soluble extracts from P. falciparum by Gavigan et al.
29
 identified high levels of neutral 
aminopeptidase activity that could release aminoacids from synthetic peptides representative of 
the products of haemoglobin digestion in the DV. This activity had a clear preference for 
synthetic substrates containing N-terminal leucine or alanine residues which was relevant since 
these are the most abundant residues in human haemoglobin (~24%).
27-29
  
The data from most studies implied that aminopeptidase activity is associated with the 
parasite cytoplasm, although ultrastructural cytochemical studies by Slomianny et al.
37
 indicated 
aminopeptidase activity may be present within the DV. We suggested that the biochemical 
characteristics of malaria aminopeptidases in cell extracts were consistent with an enzymatic 





 nor Kolakovich et al.
20
 detected aminopeptidase activity in the DV and thus it 
was proposed that haemoglobin-derived peptides generated within the DV must be transported to 
the cytosol for processing to free aminoacids by the neutral aminopeptidases. This proposal has 
been questioned recently by Ragheb et al.
33
 (see below). 
Prior to completion of the P. falciparum genome sequencing project the exact number and 
type of aminopeptidases in this malaria parasite were unknown. An active component partially 
purified from malaria extracts by Gavigan et al.
29
 using size and bestatin affinity 
chromatography had a substrate specificity in keeping with a leucyl aminopeptidase. Florent et 
al.
40
 also described a similar type of activity and were first to isolate and characterize a gene that 
encoded a malaria aminopeptidase which was identified as a member of the M1 family of alanyl 
aminopeptidases. Publication of the P. falciparum 26 Mb genome allowed the identification of 
an additional enzyme potentially responsible for the neutral aminopeptidase activity in malaria 
extracts.
40
 As it turned out, the parasite possessed two single-copy genes encoding metallo-
exopeptidases with similar activities, although their structure and classification are quite 
different. The first, is a 122 kDa M1-family alanyl aminopeptidase (PfM1AAP) with a trans-
membrane portion in its N-terminal region (as originally described by Florent et al.
40
), and the 
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3. Production of Functionally-active Recombinant PfM1AAP and PfM17LAP, 
and their Comparative Biochemistry 
 
Functionally active recombinant PfM1AAP (rPfM1AAP) and M17LAP (rPfM17LAP) have been 
produced and have proven of critical importance to the detailed characterization of the physico-
biochemical properties and three-dimensional structure of these enzymes.
41-45
 Recombinant 
expression in E. coli and/or insect cells was achieved by optimizing the gene codon usage, 
deleting regions with low complexity (including the trans-membrane portion in the case of 
PfM1APP) and removal of potential N-glycosylation sites.
41-43
 Consistent with their mammalian 
homologues, rPfM1AAP was shown to be monomeric whereas rPfM17LAP is a homo-hexamer 
of approximately 320 kDa.
42,43
 
Comparative biochemical studies have been performed with soluble malaria extracts and 
recombinant enzyme. These studies demonstrated that (a) the recombinant enzymes exhibit 
similar pH optima, pH stability and kinetic parameters against peptide substrates to their 
corresponding native forms, and (b) both native and recombinant enzymes have similar 
inhibition constants for the aminopeptidase inhibitors (such as bestatin, 1 and hPheP[CH2]Phe, 3, 
Figure 1, see below). Since rPfM1AAP and rPfM17LAP had similar properties to their native 




Analysis of enzyme kinetic data revealed that PfM1AAP and PfM17LAP have overlapping 
substrate specificities.
42,43
 PfM1AAP substrate specificity is broader than PfM17LAP’s. 
PfM1AAP can rapidly hydrolyse N-terminal leucine, alanine, arginine, and lysine; it can also 
cleave phenylalanine, tyrosine, serine, and asparagine at lower catalytic rates. In contrast, 
PfM17LAP exhibits an almost exclusive specificity for leucine; hydrolysis of N-terminal alanine, 
proline or phenylalanine is poor, and the enzyme is unable to cleave N-terminal valine, glycine, 
asparagine, glutamine, isoleucine or arginine. Because the aminoacid arginine is readily and 
uniquely cleaved by PfM1AAP, an assay for the specific detection of this enzyme in malaria 






 showed that neutral aminopeptidase activity in malaria cell extracts is 
dependent on metal ions. While both PfM1AAP and PfM17LAP possess metal ions in their 
active sites (presumably zinc by analogy with their mammalian counterparts), PfM1AAP binds a 
single metal ion whereas PfM17LAP binds two ions. Moreover, metal chelation and binding 
studies have demonstrated that one of the two active site metal ions in PfM17LAP is readily 
exchanged with other metals (such as Co, Mg and Mn) or lost by dialysis with EDTA (site 1) 
whereas the second is  more tightly bound (site 2).
46
 The single metal binding site of PfM1AAP 
exhibits tight-binding properties. These observed differences in metal ion binding properties are 
important for the interpretation of the mode and mechanism of action of aminopeptidase 
inhibitors since these commonly contain a ‘warhead’ that recognizes the active site of the 
enzyme and a specific functional ligand that complexes with the metal ion(s).
47
 In addition, the 
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difference in the susceptibility of the two enzymes to metal ion concentration may be important 





4. Are PfM1AAP and PfM17LAP Aminopeptidases Targets for Anti-malarial 
Drugs? Proof-of-Concept 
 
Early studies by Nankya-Kitaka et al.
28
 and Gavigan et al.
29
 demonstrated that the 
aminopeptidase inhibitor bestatin (1), a natural Phe-Leu dipeptide analog derived from the 
fungus Streptomyces olivoretticuli, and its derivative nitrobestatin (2, Figure 1) were potent 
inhibitors of neutral aminopeptidase activity in malaria cell extracts and could kill parasites 
(including chloroquine-resistant strains) in in vitro assays. These compounds are primarily active 
against the intraerythrocytic trophozoite stage, which exhibit the highest levels of neutral 
aminopeptidase activity. Using the recombinant enzymes we showed that bestatin and 
nitrobestatin were potent inhibitors of both P. falciparum PfM1AAP and PfM17LAP.
31,41-43
 
Recently, Harbut et al.
45
 used bestatin-based activity probes to demonstrate that PfM1AAP and 




Figure 1. A selection of aminopeptidase inhibitors investigated for their antimalarial activity. 
 
Using computer-aided design Grembecka et al.
48
 developed a series of phosphinate dipeptide 
analogs for the purpose of selectively targeting mammalian aminopeptidase N. These were also 
shown to be potent inhibitors of PfM1AAP and PfM17LAP. One of these inhibitors 
hPheP[CH2]Phe (3) inhibited recombinant aminopeptidases more effectively than bestatin and 
was also effective in vitro against P. falciparum.
31,49
 Another compound hPheP[CH2]Gly did not 
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inhibit either enzyme and had no activity against parasites in culture demonstrating a correlation 
between enzyme inhibition and parasite killing. 
Flipo et al.
50
 developed a number of dual function amide-hydroximate compounds that 
consisted of an α-substituent, a hydroxamic acid terminus (that complexes with the active site Zn 
ion), and an amide that was structurally diversified to produce potent inhibitors of PfM1AAP 
(exemplified by structure 4, Figure 1). While many of these novel compounds had IC50 values 
against native PfM1AAP (isolated from cell extracts) in the low nanomolar range, two exhibited 
an impressive (>100-fold) specificity against the malaria enzyme compared to the mammalian 
homolog (porcine kidney APN) and killed P. falciparum malaria parasites in culture (IC50 = 13 – 
59 μM). The activity of these compounds against the PfM17LAP was not determined. 
Cunningham et al.
51
 reported the evaluation of a series of α-aminoalkylphosphonate and 
phosphonopeptide inhibitors, designed against mammalian M17LAP, for their anti-malaria 
activity. They then correlated the IC50s of these compounds with their inhibitory activity against 
aminopeptidase activity in malaria cell extracts, and against recombinant PfM17LAP. A linear 
relationship between aminopeptidase inhibition and parasite killing was observed (best 
compound 5, Figure 1, IC50 =14 μM), although all compounds appeared to inhibit both 
PfM1AAP and PfM17LAP and none exhibited superior activity compared to bestatin. 
Skinner-Adams et al.
49
 performed in vivo studies with 1 and 3 (see above) using a P. c. 
chabaudi murine malaria model. Intraperitoneal administration of phosphinate 3 was shown to 
delay the appearance of parasites by 3 days and reduced parasitaemia by 96.8% compared to 
PBS-administered controls with a complete clearance of infection in the subsequent four days. 
Compound 3 was more effective than treatment with bestatin, which reduced peak parasitaemia 
by 34%. These treatments did not cause any apparent side effects in the mice. In the same study, 
the anti-malarial chloroquine delayed the appearance of parasites by six days, and reduced 
median peak parasitaemia by 93% on day 14 with a complete clearance of parasites over the 
following four days. The results of these in vivo studies, albeit performed in mouse models, are 
significant in that they provided the first and vital proof-of-concept for considering the 
PfM1AAP and PfM17LAP aminopeptidases as targets at which a new class of anti-malarial drug 
could be developed. 
 
 
5. Do PfM1AAP and PfM17LAP Function in the Same or Different Cellular 
Compartment(s)? 
 
Determining the location of the two neutral aminopeptidases within the malaria parasite is 
important in understanding their function, and is also relevant for the design of anti-malaria 
drugs that must first pass through several membranes (erythrocyte, parasitophorous and parasite 
surface) before entering the parasite to reach their target enzyme(s). PfM17LAP was detected as 
a 68-70 kDa protein in soluble extracts of P. falciparum malaria parasites, immunocytochemical 
studies located the enzyme to the parasite cytoplasm.
41,52
 This location has been confirmed by 
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confocal microscopy of live transfected parasites expressing fluorescently-tagged 
PfM17LAP
30,41,52
. Using specific inhibitors of PfM17LAP, Harbut et al.
45
 showed that killing of 
P. falciparum in culture occurs early in the intraerythrocytic cycle (ring stages) prior to the onset 
of significant haemoglobin digestion suggesting that this enzyme does not play a part in this 
process. Within the parasite cytosol, PfM17LAP may be important in the terminal stages of 
protein/peptide turnover.
30,31,41,45
 The almost exclusive specificity of PfM17LAP for leucine 
suggests that this enzyme may be essential for the generation of free leucine that can be 
exchanged for extracellular isoleucine
12,31
, an aminoacid that cannot be synthesized by the 
parasite and is the only aminoacid not found in human haemoglobin. Naughton et al.
8
 reported 
that bestatin, at 5- and 25-fold its IC50, reduced the up-take of isoleucine into P. falciparum cells 
in vitro by 20-25 and 50%, respectively, which may support this idea. 
Allary et al.
53
 showed that PfM1AAP, which contains a transmembrane domain, is expressed 
in parasite extracts as a 120 kDa protein. This protein is proteolytically processed at the N-
terminus into a fragment of 96 kDa lacking the trans-membrane domain and also a 68 kDa 
fragment that is cleaved at both N- and C-terminal ends. Anti-peptide antibodies that react with 
all three forms localized the PfM1AAP within the cytosol; no localization was observed within 
the DV although distinct accumulation around the DV was observed. A more recent study from 
this laboratory described how the 96 kDa PfM1AAP is trafficked outside the parasite into the PV 
space before being converted to the 68 kDa form and re-directed into the parasite cytoplasm and 
marginally to the DV (cell fractionation and immunoblotting experiments estimated that about 
16% of the 68 kDa form ends up in the DV).
54
 Immunocytochemistry studies in our laboratory 
using anti-peptide serum and live parasites transfected with GFP-tagged constructs indicated that 
PfM1AAP was located in the parasite cytosol.
42
 Together with its observed pH optimum for 
activity at neutral pH we interpreted these findings as indicative of a cytoplasmic function for 
PfM1AAP, possibly alone and/or in concert with PfM17LAP
31,41
 and another cytoplasmic 




By contrast, studies by Dalal and Klemba
30
 using P. falciparum parasites stably expressing 
yellow fluorescent protein-tagged PfM1AAP localized this enzyme to the DV and nucleus only. 
These cellular locations were further supported by immunoelectron microscopy
33
, and therefore 
Klemba and colleagues proposed that the PfM1AAP functions within the DV, releasing 
aminoacids from peptides generated by other endopeptidases (falcipain, plasmepsins and 
dipeptidase), and may have a separate role within the nucleus. In support of this theory, Ragheb 
et al.
33
 showed that while PfM1AAP exhibited less activity in the pH range 5.0 – 5.5 than at a 
neutral pH environment (consistent with previously published data
42
), it is still nevertheless 
stable and functional at acidic pH. The turnover rate (kcat) of the enzyme did not alter 
dramatically at pH 5.5, and although the Km did increase with decreasing pH the authors 
suggested that this could be compensated for by an increased substrate concentration within the 
lumen of the DV. Further support for the suggested function of PfM1AAP within the DV was 
provided by Harbut et al.
45
 who observed swelling of this organelle and inhibition of proteolysis 
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of haemoglobin-derived peptides when parasites where exposed to a PfM1AAP-specific bestatin-
like inhibitor in culture. 
Earlier studies by Gavigan et al.
29
 using electron microscopy did not show any effect on the 
DV when parasites where incubated in vitro with bestatin. Ragheb et al.
33
 attributed differences 
between their immunocytochemical localization observations (DV and nucleus) and that of 
Allary et al.
53 
(cytoplasm) to the use of different fixation methods. In an attempt to equate the 
collective immunocytochemical and biochemical data we have suggested that PfM1AAP could 
be associated with the DV by insertion within the DV membrane with the catalytic domain 
orientated towards the cytoplasm; in this location the enzyme may readily cleave peptides 
emerging from the DV at its optimum pH for activity,
31
 and inhibition of its function could 
conceivably perturb the DV function and structure. A recent proteomics study by Lamarque et 
al.
56
 detected PfM1AAP in DV-enriched (12-fold) preparations which seemingly provided 
support for its location in this organelle, however, these preparations also contained the 
cytoplasmic PfM17LAP. In conclusion, several issues regarding the cellular location and, hence, 
function of PfM1AAP need further elucidation. 
 
 
6. Are PfM1AAP and PfM17LAP Targets for Anti-malarial Drug 
Development? 
 
PfM1AAP and PfM17LAP are each encoded by single copy gene. Both aminopeptidase genes 
are refractory to genetic deletion strongly suggesting that knocking-out either gene is lethal to the 
parasite, and that both are required for parasite survival in the erythrocyte.
30,34
 We also generated 
transgenic P. falciparum parasites that over-expressed functionally active aminopeptidases in the 
cytoplasm and showed that these parasites were less susceptible to killing by bestatin (1) and 
hPheP[CH2]Phe (3) when compared to wild-type parasites.
42,52
 These data imply that both 
PfM1AAP and PfM17LAP are targets for the anti-malarial activity of these two broad-spectrum 
aminopeptidase inhibitors. 
Since most inhibitors used in the study of the malaria aminopeptidases block the activity of 
both PfM1AAP and PfM17LAP it remained unclear from reported in vitro and in vivo tests 
whether one or both enzymes was the targets of the aminopeptidase inhibitor-mediated killing of 
malaria parasites. However, Harbut et al.
45
 recently identified a series of activity-based probes 
(ABP) based on the scaffold of bestatin that preferentially (12-15 fold) inhibited either 
PfM1AAP or PfM17LAP (see next section). By employing these compounds in in vitro studies 
they demonstrated that (a) inhibition of either enzyme results in parasite death, supporting the 
idea that both enzymes are potential anti-malaria targets, (b) inhibition of PfM1AAP caused DV 
swelling in latter stages of asexual development whereas (c) inhibition of PfM17LAP halted the 
development of ring stage parasites before the main process of haemoglobin degradation takes 
place. These observations indicate that PfM17LAP and PfM1AAP perform different functions 
Issue in Honor of Prof. Paweł Kafarski   ARKIVOC 2012 (iv) 330-346 
 Page 339 
©
ARKAT-USA, Inc. 
within the malaria parasite and that each could be individually targeted for drug development 
(see previous Section). 
 
 
6. The PfM1AAP and PfM17LAP Active Site Pockets 
 
The structures of PfM1AAP and PfM17LAP are central to understanding both the mechanism of 
action of currently available inhibitors and to the future development of anti-malaria drugs 
targeting these enzymes. Using our recombinant proteins (see above) McGowan et al.
42,43
 
reported the X-ray crystal structures of the monomeric PfM1AAP (lacking the first 194 residues 
which contains the trans-membrane domain)
42
 and the hexameric leucine PfM17LAP,
43
 alone 
and in complex with bestatin and the phosphinate analogue hPheP[CH2]Phe. More recently, the 
same recombinant proteins were employed in the SAR studies of novel bestatin-based inhibitor 
libraries and activity-based probes by Valmourougane et al.
44
 and Harbut et al.
45
 





 motif and the substrate recognition G
460
AMEN motif are contained within 
domain IV, or the catalytic domain (Figure 2). These zinc binding and substrate coordinating 
motifs lie within the buried active site pocket that has access to the external milieu via two 
openings. One of these is formed by a helical superstructure within domain IV that forms a 28 Å 
channel that is large enough to permit peptide substrate entry to the active site. The second is a 
shallow 8 Å long channel formed by the juncture of domains I and IV and is likely to be the exit 






Figure 2. Molecular surface representation of rPfM1AAP (from pdb code 3EBH) bound to 
bestatin (left). The close-up view of the large C-terminal channel illustrates the location of the 
inhibitor within the binding site of the protein (right). 
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Molecular dynamic simulation studies by Jones et al.
57
 of an apo-PfM1AAP and a ligand-
bound complex state revealed that substrate binding in the catalytic domain are coupled to global 
conformational changes in the protein. A C-terminus -helix 10 and downstream loop proximal 
to the opening of the C-terminal channel undergoes the largest fluctuations together with the 
opening of the shallow 8 Å long channel N-terminal small channel. It was suggested that the 
function of the -helix 10 “arm” is to move peptides into the cavity as free aminoacids are 
released at the N-terminal small opening. Thus, a concerted conformational dynamic within the 
catalytic domain II ensures that as the N-terminal small channel opens to release product the -
helix 10 facilitates the movement of the peptide ligand one aminoacid at a time into the cavity by 
acting in a ‘ratchet-like’ fashion. The internal chamber may act as a vestibule or ‘waiting room’ 
for smaller peptides that get shunted along toward the active site like an assembly line.
57
 









), while a polar residue Glu
572
 located at the base of the S1 pocket is 
available to interact with the P1 side groups of the substrate.
42
 The S1 pocket accepts 






, favors small 
aliphatic residues. Interestingly, Valmourougane et al.
44
 discovered that the S1 pocket loop, 
residues 570-575, is mobile and can move to accommodate larger side chains compared to its 
mammalian counterparts, a property that could possibility be exploited for specific inhibitor 
design.  
PfM17LAP (monomer) possesses an N-terminal regulatory domain and a C-terminal 
catalytic domain that houses the active site. The two active site Zn ions are almost 3 Å apart and 















 (tightly bound site 2). The active sites of PfM17LAP (hexamer) are arranged in a 
disc-like fashion so that they are orientated inwards to form a central large catalytic cavity 
(Figure 3).
43
 In contrast to the broad substrate specificity exhibited by PfM1AAP (Leu, Ala, Phe, 
Arg, Val, Met), the structural data revealed that a very narrow and hydrophobic pocket formed in 
this enzyme accounts for its highly restricted substrate specificity (Leu and Ala). In addition, the 
active site of PfM17LAP does not contain any residue capable of forming hydrogen bonds with 
polar P1 substrate residues. Access channels formed by the N-terminal domains of the hexamer 
may play a role in determining the specificity of substrates that enter the catalytic cavity and 
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Figure 3. Molecular surface representation of rPfM17LAP monomer (from pdb code 3KR4) 
bound to bestatin (left). The close-up view illustrates how the inhibitor sits into the narrow active 
site (right). 
 
Bestatin 1 is a slow, tight-binding reversible inhibitor of malaria aminopeptidases
49,58
 that 
contains a hydroxyl group, a central nitrogen and a carbonyl group which mediates the 
interaction with the active site metal ions. This inhibitor is more effective (19-fold) against 
PfM17LAP compared to PfM1AAP
31
 because it chelates two metal ions rather than one, and 
makes a greater number of hydrogen bonds within the active site of PfM17LAP (12 as opposed 
to 8). The synthetic phosphinate dipeptide analogue 3 which exhibits fast, tight binding 
characteristics, is a more potent inhibitor of PfM17LAP and PfM1AAP than bestatin and also 
shows a greater inhibition (6-fold) for PfM17LAP compared to PfM1AAP.
31
 The Phe-rings of 
this compound bind more favorably to both enzymes and the central phosphate group provides a 
hexavalent coordination of the active site metal ions
43
. Interestingly, the binding of 
hPheP[CH2]Gly to both enzymes is dramatically reduced highlighting the need for a hydrophobic 
residue in the P1’ position. Consequently, this compound exhibits no killing against P. 
falciparum parasites in vitro.
31,49
  
The X-ray co-crystal structure of PfM1AAP bound to the dipeptide activity-based probe 
(Benzyl)Tyr-Ala (termed BTA) which was designed using the bestatin scaffold and exhibited a 
15-fold specificity for PfM1AAP over PfM17LAP was solved by Harbut et al.
45
 The structural 
data demonstrated that the probe binds to the aminopeptidase via a manner similar to bestatin, 
with only slight movement within the S1 pocket observed. Molecular modeling that employed 
PfM17LAP structure bound to bestatin showed that reduced inhibition of the BTA probe to 
PfM17LAP could be explained by a clash between the (Benzyl)Tyr residue with the narrow S1 
pocket of this enzyme. Another probe, Phe-Naphthyl (termed PNAP) exhibited a 11-fold 
specificity for PfM17LAP over PfM1AAP and was shown by crystallography to fit neatly into 
the narrow active site of PfM17LAP by formed hydrophobic interactions with the S1 and S1′ 
pockets, with some flipping of Ser550 to accommodate a P1′ naphthyl group. The reduced 
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binding of PNAP to PfM1AAP was accounted for by a clash of the P1′ naphthyl group with the 





The prevention and treatment of P. falciparum malaria is becoming difficult due to the spread of 
drug-resistant parasites.
59
 While a promising vaccine for malaria is currently in phase III trials, 
its efficacy appears to be in the order of 50%,
60
 and thus malaria drugs are still critical to control 
and elimination programs. Artemisinin (ART) derivatives in combination with one or more 
longer acting antimalarial drug(s) of a distinct chemical class, for example lumefantrine, 
mefloquine or amodiaquine
2-5
 (referred to as ART-based combination therapies, ACTs) are 
recommended for the treatment of uncomplicated P. falciparum malaria in most malaria-endemic 
areas and are arguably our last line of defense against this devastating disease. However, strains 
of P. falciparum with reduced sensitivity to ACTs are emerging, especially in the Thai-
Cambodian border and in Bangladesh.
5,61,62
 This is of great concern and highlights the urgent 
need for next generation antimalarial agents that target different parasite biochemical pathways. 
While the multistep process of haemoglobin digestion has been a notable target of 
antimalarial drug development over the last few decades, functional redundancy among enzymes 
with a similar mechanistic class (falcipains or plasmepsins) and between these classes has 
reduced the enthusiasm for the development of effective antimalarial agents targeting this 
system.
13,18,19,22
 However, unlike the plasmepsins and falcipains, PfM1AAP and PfM17LAP are 
encoded by single copy genes in both human and rodent malaria species and each are critical to 
malaria survival and are therefore a more tractable target for antimalarial drug development.
31,34
 
Substrate, inhibitor and metal binding studies together with immunocytochemical studies all 
point towards quite distinct functions for each of these aminopeptidases and offer the potential of 
developing combination therapies that would reduce the prospect of resistant malaria parasites 
arising. Furthermore, Gavigan et al.
63
 showed synergistic activity between aminopeptidase 
inhibitors and inhibitors of the falcipains and plasmepsins (albeit much lower than that observed 
between inhibitors of each these two enzyme classes) indicating that combination drugs therapies 
with these endopeptidases could also be possible.  
In addition to the PfM1AAP and the PfM17LAP, the genome of P. falciparum also contains 
other aminopeptidases with potential for anti-malaria drug development. For example, a 
cytoplasmic aspartyl aminopeptidase (PfM18AAP), that is the only malaria aminopeptidase 
capable of cleaving aspartic and glutamic acids from the N-termini of peptides, is also present in 
single copy and is essential for parasite viability.
55
 Also in consideration are the post-prolyl 
aminopeptidase (PfAPP)
32
 and dipeptidyl peptidase (cathepsin C)
25,26
 that are located in the DV 
and central to the later stages of hemoglobin degradation.   
A major challenge will be to develop compounds that exhibit selectivity for the malaria 
enzyme without off-target effects against their human homologs or other enzymes. It is relevant 
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to point out, however, that inhibitors of mammalian M1AAP and M17LAP enzymes, including 
bestatin and the hydroxamic acid metallopeptidase inhibitor tosedostat, with anti-proliferative 
effects against certain tumor cells and are well tolerated in patients.
64-66
 High resolution 
structures of PfM1AAP and the PfM17LAP in complex possess various inhibitors has revealed 
the constellation of ligand-enzyme interactions and mechanism of binding that, alongside the 
availability of functionally active recombinant enzymes, is facilitating more detailed SAR studies 
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